Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase-III trial
In brief
Week-4 responders to ivarmacitinib reach 82% EASI-75 by week 16
In a post-hoc analysis of 225 moderate-to-severe atopic dermatitis patients, 37% achieved an EASI-75 response at week 4 and went on to have an 82% response rate at week 16, compared with 47% for those without early improvement. Early responders also maintained higher skin clearance and quality-of-life scores through week 52, suggesting week-4 response may identify patients who will derive the greatest long-term benefit.
- Journal
- The Journal of dermatological treatment (Q1)
- Published
- 15 July 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Jinbo Chen, Feng Hu, Ping Zhang, Liuqing Chen
- PMID
- 42454646
- DOI
- 10.1080/09546634.2026.2637340
Why clinicians should know about it
- Picked for Dermatology (paper of the day, 16 July 2026): Early response to ivarmacitinib in moderate‑to‑severe atopic dermatitis
Abstract
BACKGROUND: Ivarmacitinib, also known as SHR0302, is a novel highly selective Janus kinase 1 inhibitor that suppresses cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD). OBJECTIVE: We aimed to explore the early response to ivarmacitinib in patients with moderate-to-severe AD and its impact on long-term efficacy. METHODS: This post hoc analysis included all patients receiving ivarmacitinib in the phase-III trial (NCT04875169). Patients were divided into early and nonearly responders, depending on whether they achieved an Eczema Area and Severity Index (EASI) 75 response at week (W) 4. RESULTS: Among the 225 patients included, 83 (36.9%) were classified as early responders and 142 (63.1%) as nonearly responders. The EASI 75 (81.9% vs. 47.2%, p < 0.001) and Investigator's Global Assessment (IGA) (56.6% vs. 28.9%, p < 0.001) response rates at W16 were higher in early responders. Additionally, early responders had higher EASI 90, EASI 100, and Scoring Atopic Dermatitis 75 and 90 response rates throughout W8 to W52. The changes in Dermatology Life Quality Index and Patient-Oriented Eczema Measure scores from baseline were greater in early responders from W8 to W52. CONCLUSION: Early response to ivarmacitinib at W4 yields better long-term efficacy in patients with moderate-to-severe AD.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.